Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tobradex ST vs Tobradex in Blepharoconjunctivitis
NCT00576251Phase 3Completed
- Sponsor
- Alcon Inc.
- Start
- Oct 2007
- Primary completion
- Feb 2008
- Modality
- Orthosteric Ligands, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tobramycin + dexamethasone in blepharoconjunctivitis (2 arms), sponsored by Alcon Inc. Primary endpoint: Percent of Patients Who Display Microbiological Success (Eradication of Baseline Pathogens at Day 4). Started Oct 2007; status: completed.
02
Drugs
tobramycin + dexamethasone
03
Conditions
blepharoconjunctivitis
Beyond the preview
Go deeper on NCT00576251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00576251.